{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T12:07:36Z","timestamp":1779192456080,"version":"3.51.4"},"reference-count":72,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,4,24]],"date-time":"2026-04-24T00:00:00Z","timestamp":1776988800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100031450","name":"LAVA Therapeutics","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100031450","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Immunology"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.clim.2026.110707","type":"journal-article","created":{"date-parts":[[2026,4,17]],"date-time":"2026-04-17T00:00:55Z","timestamp":1776384055000},"page":"110707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A trophoblast glycoprotein specific 5T4-V\u03b42 bispecific T cell engager recruits V\u03b39V\u03b42-T cells for tumor-selective cytotoxicity across solid malignancies"],"prefix":"10.1016","volume":"285","author":[{"given":"Milon","family":"de Jong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rok","family":"\u017diberna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Myrthe","family":"Veth","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elisabetta","family":"Michielon","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia","family":"Myrda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jens","family":"Seidel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryam","family":"Akbarzadeh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pauline M.","family":"van Helden","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andr\u00e9 N.","family":"Vis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sarah","family":"Derks","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roeland","family":"Lameris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanja D.","family":"de Gruijl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hans J.","family":"van der Vliet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clim.2026.110707_bb0005","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/S0140-6736(23)00521-4","article-title":"T-cell-engaging bispecific antibodies in cancer","volume":"402","author":"van de Donk","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.clim.2026.110707_bb0010","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1056\/NEJMoa2312948","article-title":"Blinatumomab for MRD-negative acute lymphoblastic leukemia in adults","volume":"391","author":"Litzow","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.clim.2026.110707_bb0015","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13020287","article-title":"Overcoming challenges for CD3-bispecific antibody therapy in solid tumors","volume":"13","author":"Middelburg","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.clim.2026.110707_bb0020","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.ymeth.2018.10.026","article-title":"Bispecific T-cell engagers: towards understanding variables influencing the in vitro potency and tumor selectivity and their modulation to enhance their efficacy and safety","volume":"154","author":"Ellerman","year":"2019","journal-title":"Methods"},{"key":"10.1016\/j.clim.2026.110707_bb0025","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15102824","article-title":"T-cell engagers in solid cancers-current landscape and future directions","volume":"15","author":"Shanshal","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clim.2026.110707_bb0030","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1002\/dvdy.20482","article-title":"Embryonic expression of murine 5T4 oncofoetal antigen is associated with morphogenetic events at implantation and in developing epithelia","volume":"233","author":"Barrow","year":"2005","journal-title":"Dev. Dyn."},{"key":"10.1016\/j.clim.2026.110707_bb0035","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1038\/bjc.1994.173","article-title":"Prognostic significance of 5T4 oncofetal antigen expression in colorectal carcinoma","volume":"69","author":"Starzynska","year":"1994","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clim.2026.110707_bb0040","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1046\/j.1525-1438.1995.05040269.x","article-title":"5T4 oncofetal antigen expression in ovarian carcinoma","volume":"5","author":"Wrigley","year":"1995","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.clim.2026.110707_bb0045","first-page":"1923","article-title":"Low intercellular adhesion molecule 1 and high 5T4 expression on tumor cells correlate with reduced disease-free survival in colorectal carcinoma patients","volume":"3","author":"Mulder","year":"1997","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2026.110707_bb0050","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/00042737-199806000-00008","article-title":"5T4 oncofetal antigen in gastric carcinoma and its clinical significance","volume":"10","author":"Starzynska","year":"1998","journal-title":"Eur. J. Gastroenterol. Hepatol."},{"key":"10.1016\/j.clim.2026.110707_bb0055","doi-asserted-by":"crossref","first-page":"4236","DOI":"10.1158\/0008-5472.CAN-10-3919","article-title":"Delineation of a cellular hierarchy in lung cancer reveals an oncofetal antigen expressed on tumor-initiating cells","volume":"71","author":"Damelin","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2026.110707_bb0060","article-title":"Cancer stem cell mobilization and therapeutic targeting of the 5T4 oncofetal antigen","volume":"7","author":"Harrop","year":"2019","journal-title":"Ther. Adv. Vaccines Immunother."},{"key":"10.1016\/j.clim.2026.110707_bb0065","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00262-016-1917-3","article-title":"5T4 oncofoetal antigen: an attractive target for immune intervention in cancer","volume":"66","author":"Stern","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2026.110707_bb0070","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1136\/ijgc-2023-005200","article-title":"A randomized phase II trial to examine modified vaccinia Ankara-5T4 vaccine in patients with relapsed asymptomatic ovarian cancer (TRIOC)","volume":"34","author":"Michael","year":"2024","journal-title":"Int. J. Gynecol. Cancer"},{"key":"10.1016\/j.clim.2026.110707_bb0075","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s10637-016-0419-7","article-title":"First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors","volume":"35","author":"Shapiro","year":"2017","journal-title":"Investig. New Drugs"},{"key":"10.1016\/j.clim.2026.110707_bb0080","doi-asserted-by":"crossref","first-page":"4116","DOI":"10.1200\/JCO.2008.20.2515","article-title":"Phase I dose escalation, pharmacokinetic and pharmacodynamic study of naptumomab estafenatox alone in patients with advanced cancer and with docetaxel in patients with advanced non-small-cell lung cancer","volume":"27","author":"Borghaei","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2026.110707_bb0085","doi-asserted-by":"crossref","first-page":"S524","DOI":"10.1016\/j.annonc.2024.08.734","volume":"35","author":"Marron","year":"2024","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2026.110707_bb0090","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1038\/sj.bjc.6603567","article-title":"A phase II study of a 5T4 oncofoetal antigen tumour-targeted superantigen (ABR-214936) therapy in patients with advanced renal cell carcinoma","volume":"96","author":"Shaw","year":"2007","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clim.2026.110707_bb0095","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1158\/1535-7163.MCT-24-0052","article-title":"Targeting tumor antigen 5T4 using CAR T cells for the treatment of acute myeloid leukemia","volume":"24","author":"Harrop","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.clim.2026.110707_bb0100","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1097\/CJI.0b013e3181ace876","article-title":"Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial","volume":"32","author":"Amato","year":"2009","journal-title":"J. Immunother."},{"key":"10.1016\/j.clim.2026.110707_bb0105","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2023.2229101","article-title":"Exploration of the antibody-drug conjugate clinical landscape","volume":"15","author":"Maecker","year":"2023","journal-title":"MAbs"},{"key":"10.1016\/j.clim.2026.110707_bb0110","doi-asserted-by":"crossref","DOI":"10.26508\/lsa.202201481","article-title":"Mechanistic and pharmacodynamic studies of DuoBody-CD3x5T4 in preclinical tumor models","volume":"5","author":"Kemper","year":"2022","journal-title":"Life Sci. Alliance."},{"key":"10.1016\/j.clim.2026.110707_bb0115","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1111\/imr.12923","article-title":"Immune recognition of phosphoantigen-butyrophilin molecular complexes by \u03b3\u03b4 t cells","volume":"298","author":"Uldrich","year":"2020","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.clim.2026.110707_bb0120","doi-asserted-by":"crossref","DOI":"10.1126\/science.aay5516","article-title":"Butyrophilin 2A1 is essential for phosphoantigen reactivity by \u03b3\u03b4 T cells","volume":"367","author":"Rigau","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.clim.2026.110707_bb0125","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.915837","article-title":"Gamma delta T-cell based cancer immunotherapy: past-present-future","volume":"13","author":"Saura-Esteller","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110707_bb0130","doi-asserted-by":"crossref","first-page":"4920","DOI":"10.4049\/jimmunol.168.10.4920","article-title":"Patterns of chemokine receptor expression on peripheral blood \u03b3\u03b4 T lymphocytes: strong expression of CCR5 is a selective feature of V\u03b42\/V\u03b39 \u03b3\u03b4 T cells1","volume":"168","author":"Glatzel","year":"2002","journal-title":"J. Immunol."},{"key":"10.1016\/j.clim.2026.110707_bb0135","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1038\/nm.3909","article-title":"The prognostic landscape of genes and infiltrating immune cells across human cancers","volume":"21","author":"Gentles","year":"2015","journal-title":"Nat. Med."},{"key":"10.1016\/j.clim.2026.110707_bb0140","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2017.1284723","article-title":"Assessment of tumor-infiltrating TCRV\u03b39V\u03b42 \u03b3\u03b4 lymphocyte abundance by deconvolution of human cancers microarrays","volume":"6","author":"Tosolini","year":"2017","journal-title":"OncoImmunology"},{"key":"10.1016\/j.clim.2026.110707_bb0145","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2326-6066.CIR-23-0189","article-title":"A bispecific gammadelta t-cell engager targeting EGFR activates a potent Vgamma9Vdelta2 T cell-mediated immune response against EGFR-expressing tumors","volume":"11","author":"King","year":"2023","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.clim.2026.110707_bb0150","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1158\/1078-0432.CCR-20-4576","article-title":"A bispecific single-domain antibody boosts autologous Vgamma9Vdelta2-T cell responses toward CD1d in chronic lymphocytic leukemia","volume":"27","author":"de Weerdt","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.clim.2026.110707_bb0155","doi-asserted-by":"crossref","first-page":"2577","DOI":"10.1200\/JCO.2022.40.16_suppl.2577","article-title":"Phase i dose escalation of LAVA-051, a novel bispecific gamma-delta t-cell engager (gammabody), in relapsed\/refractory hematological malignancies","volume":"40","author":"Broijl","year":"2022","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2026.110707_bb0160","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2672","article-title":"Phase I\/II trial of LAVA-1207, a novel bispecific gamma-delta t-cell engager alone, or with low dose IL-2 or pembrolizumab, in metastatic castration resistant prostate cancer (mCRPC)","volume":"42","author":"Mehra","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.clim.2026.110707_bb0165","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.111289","article-title":"Leveraging V\u03b39V\u03b42 T cells against prostate cancer through a VHH-based PSMA-V\u03b42 bispecific t cell engager","volume":"27","author":"King","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.clim.2026.110707_bb0170","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1158\/0008-5472.CAN-13-0675","article-title":"Novel bispecific antibodies increase \u03b3\u03b4 T-cell cytotoxicity against pancreatic cancer cells","volume":"74","author":"Oberg","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2026.110707_bb0175","article-title":"A bispecific T cell engager recruits both type 1 NKT and V\u03b39V\u03b42-T cells for the treatment of CD1d-expressing hematological malignancies","volume":"4","author":"Lameris","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.clim.2026.110707_bb0180","doi-asserted-by":"crossref","first-page":"2274","DOI":"10.1038\/s41375-021-01122-7","article-title":"Selective recruitment of \u03b3\u03b4 T cells by a bispecific antibody for the treatment of acute myeloid leukemia","volume":"35","author":"Ganesan","year":"2021","journal-title":"Leukemia"},{"key":"10.1016\/j.clim.2026.110707_bb0185","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1038\/leu.2017.41","article-title":"Frequency of regulatory t cells determines the outcome of the T-cell-engaging antibody blinatumomab in patients with b-precursor ALL","volume":"31","author":"Duell","year":"2017","journal-title":"Leukemia"},{"key":"10.1016\/j.clim.2026.110707_bb0190","doi-asserted-by":"crossref","first-page":"787","DOI":"10.3324\/haematol.2023.283758","article-title":"Regulatory T cells hamper the efficacy of T-cell-engaging bispecific antibody therapy","volume":"109","author":"Casey","year":"2024","journal-title":"Haematologica"},{"key":"10.1016\/j.clim.2026.110707_bb0195","first-page":"345","article-title":"Exceptional lethality for nude mice of cells derived from a primary human melanoma","volume":"45","author":"Lockshin","year":"1985","journal-title":"Cancer Res."},{"key":"10.1016\/j.clim.2026.110707_bb0200","doi-asserted-by":"crossref","first-page":"16297","DOI":"10.1074\/jbc.RA119.007796","article-title":"The human cytomegalovirus-encoded g protein-coupled receptor UL33 exhibits oncomodulatory properties","volume":"294","author":"van Senten","year":"2019","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.clim.2026.110707_bb0205","article-title":"A bispecific nanobody approach to leverage the potent and widely applicable tumor cytolytic capacity of V\u03b39V\u03b42-T cells","volume":"7","author":"de Bruin","year":"2017","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clim.2026.110707_bb0210","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s00262-019-02320-0","article-title":"Autologous tumor cell vaccination combined with systemic CpG-B and IFN-alpha promotes immune activation and induces clinical responses in patients with metastatic renal cell carcinoma: a phase II trial","volume":"68","author":"Koster","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2026.110707_bb0215","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1023\/A:1008363601515","article-title":"Skin tests predict survival after autologous tumor cell vaccination in metastatic melanoma: experience in 81 patients","volume":"11","author":"Baars","year":"2000","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.clim.2026.110707_bb0220","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1111\/imm.12635","article-title":"Generation and characterization of CD1d-specific single-domain antibodies with distinct functional features","volume":"149","author":"Lameris","year":"2016","journal-title":"Immunology"},{"key":"10.1016\/j.clim.2026.110707_bb0225","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s00262-006-0180-4","article-title":"Efficient inhibition of EGFR signaling and of tumour growth by antagonistic anti-EFGR nanobodies","volume":"56","author":"Roovers","year":"2007","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2026.110707_bb0230","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1084\/jem.20112655","article-title":"Potent and broad neutralization of HIV-1 by a llama antibody elicited by immunization","volume":"209","author":"McCoy","year":"2012","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.clim.2026.110707_bb0235","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.clim.2016.06.012","article-title":"Highly specific and potently activating Vgamma9Vdelta2-T cell specific nanobodies for diagnostic and therapeutic applications","volume":"169","author":"de Bruin","year":"2016","journal-title":"Clin. Immunol."},{"issue":"2024","key":"10.1016\/j.clim.2026.110707_bb0240","article-title":"V\u03b42 T-cell engagers bivalent for V\u03b42-TCR binding provide anti-tumor immunity and support robust V\u03b39V\u03b42 T-cell expansion","volume":"14","author":"King","year":"2024","journal-title":"Front. Oncol."},{"key":"10.1016\/j.clim.2026.110707_bb0245","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1038\/leu.2012.18","article-title":"5T4 oncofetal antigen is expressed in high risk of relapse childhood pre-B acute lymphoblastic leukemia and is associated with a more invasive and chemotactic phenotype","volume":"26","author":"Castro","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.clim.2026.110707_bb0250","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0009982","article-title":"CXCR4 mediated chemotaxis is regulated by 5T4 oncofetal glycoprotein in mouse embryonic cells","volume":"5","author":"Southgate","year":"2010","journal-title":"PLoS One"},{"key":"10.1016\/j.clim.2026.110707_bb0255","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.yexcr.2018.02.001","article-title":"The 5T4 oncofetal glycoprotein does not act as a general organizer of the CXCL12 system in cancer cells","volume":"364","author":"Puchert","year":"2018","journal-title":"Exp. Cell Res."},{"key":"10.1016\/j.clim.2026.110707_bb0260","first-page":"5467","article-title":"CXCL12 receptor preference, signal transduction, biological response and the expression of 5T4 oncofoetal glycoprotein","volume":"125","author":"McGinn","year":"2012","journal-title":"J. Cell Sci."},{"key":"10.1016\/j.clim.2026.110707_bb0265","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/mco2.34","article-title":"Effective antitumor activity of 5T4-specific CAR-T cells against ovarian cancer cells in vitro and xenotransplanted tumors in vivo","volume":"1","author":"Guo","year":"2020","journal-title":"MedComm"},{"key":"10.1016\/j.clim.2026.110707_bb0270","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1038\/bjc.1990.20","article-title":"Immunohistological distribution of 5T4 antigen in normal and malignant tissues","volume":"61","author":"Southall","year":"1990","journal-title":"Br. J. Cancer"},{"key":"10.1016\/j.clim.2026.110707_bb0275","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1016\/j.humimm.2010.06.014","article-title":"Impact of age, gender, and race on circulating \u03b3\u03b4 t cells","volume":"71","author":"Cairo","year":"2010","journal-title":"Hum. Immunol."},{"key":"10.1016\/j.clim.2026.110707_bb0280","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S1368-8375(00)00057-9","article-title":"The pattern of expression of the 5T4 oncofoetal antigen on normal, dysplastic and malignant oral mucosa","volume":"37","author":"Ali","year":"2001","journal-title":"Oral Oncol."},{"key":"10.1016\/j.clim.2026.110707_bb0285","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1038\/s12276-024-01272-5","article-title":"Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology","volume":"56","author":"Thorel","year":"2024","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.clim.2026.110707_bb0290","article-title":"Patient-derived organoids as a predictive biomarker for treatment response in cancer patients","volume":"5","author":"Wensink","year":"2021","journal-title":"npj Precis. Oncol."},{"key":"10.1016\/j.clim.2026.110707_bb0295","doi-asserted-by":"crossref","DOI":"10.15252\/embj.2018100928","article-title":"3D model for CAR-mediated cytotoxicity using patient-derived colorectal cancer organoids","volume":"38","author":"Schnalzger","year":"2019","journal-title":"EMBO J."},{"key":"10.1016\/j.clim.2026.110707_bb0300","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1038\/s42003-024-06682-9","article-title":"CD3-engaging bispecific antibodies trigger a paracrine regulated wave of T-cell recruitment for effective tumor killing","volume":"7","author":"Liao","year":"2024","journal-title":"Commun. Biol."},{"key":"10.1016\/j.clim.2026.110707_bb0305","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/s00262-016-1927-1","article-title":"A novel three-dimensional heterotypic spheroid model for the assessment of the activity of cancer immunotherapy agents","volume":"66","author":"Herter","year":"2017","journal-title":"Cancer Immunol. Immunother."},{"key":"10.1016\/j.clim.2026.110707_bb0310","doi-asserted-by":"crossref","first-page":"732","DOI":"10.1158\/2326-6066.CIR-13-0167","article-title":"CD1d-restricted antigen presentation by V\u03b39V\u03b42-T cells requires trogocytosis","volume":"2","author":"Schneiders","year":"2014","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.clim.2026.110707_bb0315","doi-asserted-by":"crossref","first-page":"5856","DOI":"10.4049\/jimmunol.1202879","article-title":"Imprinting of lymphocytes with melanoma antigens acquired by trogocytosis facilitates identification of tumor-reactive t cells","volume":"190","author":"Eisenberg","year":"2013","journal-title":"J. Immunol."},{"issue":"2017","key":"10.1016\/j.clim.2026.110707_bb0320","article-title":"Camelid single-domain antibodies: historical perspective and future outlook","volume":"8","author":"Arbabi-Ghahroudi","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110707_bb0325","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002444","article-title":"Dichotomous impact of affinity on the function of T cell engaging bispecific antibodies","volume":"9","author":"Poussin","year":"2021","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.clim.2026.110707_bb0330","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"Rossotti","year":"2022","journal-title":"FEBS J."},{"key":"10.1016\/j.clim.2026.110707_bb0335","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1158\/1535-7163.MCT-22-0395","article-title":"The bispecific tumor antigen-conditional 4\u20131BB x 5T4 agonist, ALG.APV-527, mediates strong T-cell activation and potent antitumor activity in preclinical studies","volume":"22","author":"Nelson","year":"2023","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.clim.2026.110707_bb0340","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1186\/s40164-017-0074-5","article-title":"Changes in clinical laboratory parameters and pharmacodynamic markers in response to blinatumomab treatment of patients with relapsed\/refractory ALL","volume":"6","author":"N\u00e4gele","year":"2017","journal-title":"Exp. Hematol. Oncol."},{"key":"10.1016\/j.clim.2026.110707_bb0345","article-title":"The role of cytokines in predicting the response and adverse events related to immune checkpoint inhibitors","volume":"12","author":"Wang","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.clim.2026.110707_bb0350","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-023-41634-7","article-title":"Modulation of lytic molecules restrain serial killing in \u03b3\u03b4 T lymphocytes","volume":"14","author":"Sandoz","year":"2023","journal-title":"Nat. Commun."},{"key":"10.1016\/j.clim.2026.110707_bb0355","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-23-0228","article-title":"Emerging strategies for the prevention of immune toxicities associated with T cell-engaging cancer therapies","volume":"5","author":"Kowalski","year":"2024","journal-title":"Blood Cancer Discov."},{"key":"10.1016\/j.clim.2026.110707_bb0360","doi-asserted-by":"crossref","first-page":"9534","DOI":"10.1200\/JCO.2024.42.16_suppl.9534","article-title":"EVICTION study: ICT01, an anti-Butyrophilin 3A monoclonal antibody activating \u03b39\u03b42 t cells in combination with pembrolizumab in checkpoint inhibitor refractory melanoma","volume":"42","author":"Champiat","year":"2024","journal-title":"J. Clin. Oncol."}],"container-title":["Clinical Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000458?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521661626000458?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,19]],"date-time":"2026-05-19T11:36:35Z","timestamp":1779190595000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521661626000458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":72,"alternative-id":["S1521661626000458"],"URL":"https:\/\/doi.org\/10.1016\/j.clim.2026.110707","relation":{},"ISSN":["1521-6616"],"issn-type":[{"value":"1521-6616","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A trophoblast glycoprotein specific 5T4-V\u03b42 bispecific T cell engager recruits V\u03b39V\u03b42-T cells for tumor-selective cytotoxicity across solid malignancies","name":"articletitle","label":"Article Title"},{"value":"Clinical Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clim.2026.110707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"110707"}}